Takeaways: Health Canada’s authorization expands Cytokinetics’ commercial reach for Myqorzo in oHCM, positioning it against Bristol Myers Squibb’s Camzyos through another once-daily cardiac myos...
Takeaways: Health Canada’s authorization expands Cytokinetics’ commercial reach for Myqorzo in oHCM, positioning it against Bristol Myers Squibb’s Camzyos through another once-daily cardiac myos...